Sienna's acne photoparticle therapy misses in two pivotal trials

Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) said SNA-001 missed the primary and secondary endpoints in a pair of pivotal trials to treat moderate to severe acne vulgaris.

The candidate is a topical photoparticle therapy targeting the sebaceous gland that is designed to absorb laser light and convert the light energy into heat to facilitate local tissue injury. SNA-001 is being developed as a Class II medical device under FDA's 510(k) marketing clearance pathway...